Janssen Announces European Commission Approval of Imbruvica▼(ibrutinib) for Expanded Use in Two Indications

Posted in Biotech

August 13, 2019 • 2 min read

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications. This includes the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia...

Novartis Addresses FDA Data Manipulation Inquiry

Posted in Biotech

August 07, 2019 • 2 min read

The FDA announced they were informed by AveXis, Inc., the gene therapy subsidiary of Novartis, that data was knowingly manipulated and inaccurate in their application for Zolgensma...